Volume 19, Number 7—July 2013
MDR TB Transmission, Singapore
Highlight and copy the desired format.
|EID||Chee C, Hsu L, Sng L, Leo Y, Cutter J, Wang Y, et al. MDR TB Transmission, Singapore. Emerg Infect Dis. 2013;19(7):1151-1152. https://dx.doi.org/10.3201/eid1907.120372|
|AMA||Chee C, Hsu L, Sng L, et al. MDR TB Transmission, Singapore. Emerging Infectious Diseases. 2013;19(7):1151-1152. doi:10.3201/eid1907.120372.|
|APA||Chee, C., Hsu, L., Sng, L., Leo, Y., Cutter, J., & Wang, Y. (2013). MDR TB Transmission, Singapore. Emerging Infectious Diseases, 19(7), 1151-1152. https://dx.doi.org/10.3201/eid1907.120372.|
To the Editor: Over the past decade, the proportion of pulmonary multidrug-resistant tuberculosis (MDR TB) cases among Singapore-born patients remained low, whereas that among foreign-born patients was 10× higher (1,2). Since 2005, Singapore has experienced a sharp increase in the number of MDR TB cases from high-prevalence countries (3). We report local transmission of MDR TB in 2011, from a short-stay visitor to 2 Singapore-born persons in a correctional setting.
The index case-patient was a 34-year-old Burmese man (patient A) arrested 10 months after entering Singapore. A screening radiograph taken 2 days after arrest showed a right upper lobe cavitary lesion. The man was referred to the TB Control Unit. He had been coughing for 3 months but had no other concurrent conditions. When the abnormal radiograph results became known, the man was isolated within the prison. Sputum was collected, and first-line anti-TB drugs were administered pending sputum results. The sputum smear had 3+ acid-fast bacilli (AFB); mutations of the rpoB and katG genes were indicated by testing with GenoType MTDRplus (Hain Lifescience, Nehren, Germany). The patient’s treatment regimen was modified accordingly; appropriate second-line anti-TB treatment was started 14 days after he entered the institution. Mycobacterium tuberculosis complex (MTC) grew from sputum in 9 days; phenotypic drug-susceptibility testing (DST) demonstrated resistance to rifampin, isoniazid, streptomycin, and ethambutol and susceptibility to pyrazinamide, ethionamide, kanamycin, and ofloxacin.
One month after patient A was arrested, a Singapore-born man (patient B) in a public hospital received a diagnosis of HIV infection (67 CD4 cells/μL) and Pneumocystis jirovecii pneumonia. He was not an identified contact of patient A, although his job entailed accompanying prisoners from remand centers to justice courts. Antiretroviral treatment (ART) given 1 month after HIV diagnosis resulted in fever 7 days later. A repeat chest radiograph showed increased opacities in the left upper zone. Sputum smear was 4+ for AFB, and MTC with rpoB gene mutation was detected (Xpert MTB/RIF; Cepheid, Sunnyvale CA, USA). Second-line anti-TB drugs were administered. MTC was grown in sputum and blood in 14 and 32 days, respectively; phenotypic DST 8 weeks later showed a susceptibility profile that was identical (except for ethambutol susceptibility) to that of patient A.
Patient C was a 43-year-old Singapore-born man arrested 1 month after receiving an HIV diagnosis and beginning ART. He withheld his HIV status from prison authorities. He shared a cell with patient A for ≈48 hours at the remand center before the chest radiograph for patient A was taken. Patient C was released after 2 days and screened as a contact 2 months later; CD4 count was <20 cells/μL despite ART. Physical examination showed peripheral lymphadenopathy. T-SPOT.TB test (Oxford Immunotec Ltd., Abingdon, UK) result was negative, chest radiographs were unremarkable, and 2 sputum smears were negative for AFB (corresponding specimens for TB culture were negative). These findings were communicated to the patient’s primary physician. He was hospitalized 3 months later with fever and cough for 5 days but discharged himself, against medical advice, after 2 days. After 11 days, he was readmitted in septic shock to another hospital, at which time his sputum smear was positive for AFB and chest radiograph showed an increased right paratracheal stripe with right lower zone opacities. A bronchoesophageal fistula was also diagnosed, for which he declined intervention. Isoniazid, ethambutol, pyrazinamide, and rifabutin (his second-line ART regimen was incompatible with rifampin) were prescribed, and he discharged himself, against medical advice. After 5 days, he was readmitted with worsening cough; second-line anti-TB medications were instituted when his sputum specimen results were reported 8 weeks later as being phenotypically resistant to rifampin, isoniazid, and streptomycin. DST results for ethambutol were discrepant for isolates cultured from 2 sputum specimens and tested in 2 laboratories.
DNA genotyping by spoligotyping (Ocimum Biosolutions, Hyderabad, India) (4) showed that the isolates from all 3 patients belonged to type 467 H3, according to the SITVIT2 database (www.pasteur-guadeloupe.fr:8081/SITVITDemo/). Mycobacterial interspersed repetitive units–variable number tandem repeat genotyping with a 24-loci panel (Genoscreen, Lille, France) (5) similarly showed identical profiles (Figure). No other isolates in our database had matching profiles.
The cases reported here echo previous institutional outbreaks of MDR TB in industrialized countries (6–8). They are a reminder of the potentially devastating consequences when HIV and MDR TB intersect and the need for infection control measures where vulnerable and/or high-risk groups congregate. For patients A and B, rapid genotypic DST expedited the MDR TB diagnosis and institution of appropriate treatment and isolation measures and curtailed further spread. The unmasking immune reconstitution inflammatory syndrome that developed in patient B exemplifies the need for TB screening before starting ART in patients from countries with medium-to-high TB prevalence. For patient C, the several-week delay in instituting second-line TB medications could have been avoided had hospital medical teams been aware of his recent MDR TB exposure.
A recent update documented the highest rates of global MDR TB in 2009 and 2010 (9). Our experience reported here underscores the need to be constantly mindful of this infectious disease threat in our increasingly borderless world, even in countries where incidence of MDR TB is low.
- Ministry of Health. Communicable disease surveillance report in Singapore 2010. Singapore: The Ministry; 2011.
- Chee CBE, KhinMar KW, Cutter J, Wang YT. The imminent threat of multidrug-resistant tuberculosis in Singapore. Singapore Med J 2012;53:238–40. PMID: 22511044
- Kyi Win KM, Chee CBE, Shen L, Wang YT, Cutter J. Tuberculosis among foreign-born persons, Singapore, 2000–2009. Emerg Infect Dis. 2011;17:517–9.
- Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol. 1997;35:907–14 .
- Supply P, Allix C, Lesjean S, Cardoso-Oelemann M, Rusch-Gerdes S, Willery E, Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J Clin Microbiol. 2006;44:4498–510 .
- Valway SE, Greifinger RB, Papania M, Kilburn JO, Woodley C, DiFerdinando GT, Multidrug-resistant tuberculosis in the New York State prison system, 1990–1991. J Infect Dis. 1994;170:151–6 .
- Edlin BR, Tokars JI, Grieco MH, Crawford JT, Williams J, Sordillo EM, An outbreak of multidrug-resistant tuberculosis among hospitalised patients with the acquired immunodeficiency syndrome. N Engl J Med. 1992;326:1514–21 .
- Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, Finlay A, HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis. 2007;196(Suppl 1):S86–107 .
- Zignol M, van Gemert W, Falzon D, Sismanidis C, Glaziou P, Floyd K, Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007–2010. Bull World Health Organ. 2012;90:111–119D .
- Figure. . Spoligotype and 24-loci MIRU-VNTR typing results for Mycobacterium tuberculosis complex isolates recovered from 3 patients with multidrug-resistant tuberculosis (TB). Patient A (index case-patient), Burma-born man with TB, incarcerated in...
Please use the form below to submit correspondence to the authors or contact them at the following address:
Cynthia B. E. Chee, TB Control Unit, Department of Respiratory and Critical Care Medicine, Tan Tock Seng Hospital, 144 Moulmein Rd, Singapore 308089
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: June 19, 2013
- Page last updated: June 19, 2013
- Page last reviewed: June 19, 2013
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)